

ALLIGATOR BIOSCIENCE GRANTED FIRST U.S. PATENT FOR NEO-X-PRIME™ BISPECIFIC ANTIBODY ATOR-4066 FOR CANCER TREATMENT

Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. US 11,873,348 covering ATOR-4066, a Neo-X-Prime™ next generation bispecific antibody targeting CD40 and CEACAM5, in the treatment of cancer.

The patent, titled "Novel peptides", provides ATOR-4066 with protection regarding methods of treating cancer and/or a tumor using a bispecific antibody comprising the complementarity-determining regions (CDRs) of the ATOR-4066 molecule.

The patent is the first patent of the ATOR-4066 intellectual property portfolio which is expected to strengthen as more patents are filed and granted. Its accelerated application was part of the Cancer Immunotherapy Pilot program, which provided a fast-track review for cancer immunotherapy-related patent applications in the U.S.

*"By simultaneously targeting CD40 and a tumor associated antigen, ATOR-4066 has demonstrated superior anti-tumor immunity, and we see medical opportunities for this first-in-class preclinical asset in , multiple cancer indications, targeting both cold and hot tumor types " said **Søren Bregenholt, CEO of Alligator Bioscience**. "The granting of this patent is an important step in the ongoing development of ATOR-4066 and we place great emphasis on the protection of our intellectual property as a key component of our drug development program and our overall business strategy."*

ATOR-4066 was developed by Alligator's proprietary Neo-X-Prime™ platform that generates bispecific conditional antibody agonists able to significantly boost dendritic cells and T-cell activation by connecting them to tumor debris.

PRESS RELEASE

16 January 2024 11:00:00 CET



For further information, please contact:

Søren Bregenholt, CEO

E-mail: soren.bregenholt@alligatorbioscience.com

Phone: +46 (0) 46 540 82 00

LifeSci Advisors

Investor Relations

Guillaume van Renterghem

E-mail: gvanrenterghem@lifesciadvisors.com

Phone: +41 (0) 76 735 01 31

The information was submitted for publication, through the agency of the contact person set out above, at 11:00 a.m. CET on January 16, 2024.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

[Alligator Bioscience Granted First U.S. Patent for Neo-X-Prime™ Bispecific Antibody ATOR-4066 for Cancer Treatment](#)